

Andrey Loboda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9211006/publications.pdf>

Version: 2024-02-01

19
papers

8,093
citations

516710

16
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

14064
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. <i>Clinical Cancer Research</i> , 2022, 28, 1680-1689.	7.0	32
2	Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 427-439.	4.1	10
3	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	7.0	21
4	Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. <i>Onc Immunology</i> , 2021, 10, 1896643.	4.6	28
5	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	123
6	ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. <i>Molecular Cancer Research</i> , 2021, 19, 702-716.	3.4	32
7	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1564-1573.	7.0	33
8	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	12.6	1,575
9	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	30.7	1,071
10	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. <i>Cancer Cell</i> , 2017, 32, 654-668.e5.	16.8	457
11	IFN-̳-related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	8.2	2,560
12	Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. <i>Journal of Clinical Oncology</i> , 2017, 35, 1-1.	1.6	8
13	Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 839-851.	2.8	11
14	Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. <i>Molecular Neurodegeneration</i> , 2016, 11, 31.	10.8	34
15	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	30.7	1,592
16	Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2014, 9, e113937.	2.5	18
17	Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling. <i>American Journal of Pathology</i> , 2011, 179, 37-45.	3.8	269
18	A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. <i>BMC Medical Genomics</i> , 2010, 3, 26.	1.5	124

#	ARTICLE	IF	CITATIONS
19	Diurnal variation of the human adipose transcriptome and the link to metabolic disease. BMC Medical Genomics, 2009, 2, 7.	1.5	93